Hormone therapy for prostate cancer: Guidelines versus clinical practice

European Urology, Supplements

Volumn 5, Issue 3 SPEC. ISS., 2006, Pages 362-368

  Alcaraz, Antonio ^a   Teillac, Pierre ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Clinical practice; Guidelines; Hormone therapy; Prostate cancer; Radiation therapy; Radical prostatectomy

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; GLEASON SCORE; HORMONAL THERAPY; HUMAN; LIFE EXPECTANCY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

EID: 33644749208     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.01.001     Document Type: Article

References (16)

1. G. Aus, C.C. Abbou, and M. Bolla EAU guidelines on prostate cancer Eur Urol 48 2005 546 551
2. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Updated full version, http://www.uroweb.org, March 2005.
3. G.E. Hanks, A.L. Hanlon, and T.E. Schultheiss Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions Int J Radiat Oncol Biol Phys 41 1998 501 510
4. S.A. Leibel, M.J. Zelefsky, and G.J. Kutcher The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate Semin Oncol 21 1994 580 597
5. M.J. Zelefsky, S.A. Leibel, and P.B. Gaudin Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer Int J Radiat Oncol Biol Phys 41 1998 491 500
6. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 2002 103 108
7. G.E. Hanks, T.F. Pajak, and A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978
8. M.V. Pilepich, K. Winter, and M.J. John Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
9. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290
10. S.R. Bott Management of recurrent disease after radical prostatectomy Prostate Cancer Prostatic Dis 7 2004 211 216
11. G.D. Grossfeld, D.M. Stier, and S.C. Flanders Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database J Urol 160 1998 1398 1404
12. A.W. Partin, J.D. Pearson, and P.K. Landis Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases Urology 43 1994 649 659
13. C.R. Pound, A.W. Partin, M.A. Eisenberger, D.W. Chan, J.D. Pearson, and P.C. Walsh Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
14. L. Klotz Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer Eur Urol 47 2005 16 21
15. Prostate Cancer Trialists' Collaborative Group Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials Lancet 355 2000 1491 1498
16. D.J. Samson, J. Seidenfeld, and B. Schmitt Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma Cancer 95 2002 361 376